NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines

NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines
 
 - Patent claims cover technology for rapid, efficient, and uniform production of VLP vaccines from strains of seasonal and pandemic influenza.
ROCKVILLE, Md., July 27 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the issuance of U.S. Patent No. 7,763,450 for "Functional Influenza Virus-Like Particles (VLPS)".  The patent covers the use of influenza gene sequences for high-yield production of consistent influenza VLP vaccines to protect against current and future seasonal and pandemic strains of influenza viruses.

Novavax's newly patented influenza vaccine technology utilizes hemagglutinin (HA) and neuraminidase (NA), major proteins found on the surface of the influenza virus together with a single influenza matrix 1 (M1) protein, to form the core of the influenza VLP.  As new influenza strains emerge, Novavax's technology allows HA and NA to be engineered to match strains recommended by U.S. and world health regulatory authorities and then combined with a universal M1 protein.  Novavax has identified an M1 protein that efficiently forms VLPs from multiple influenza strains, including the human A and B strains that are currently responsible for the disease world wide.  This process promotes rapid and efficient production of VLPs that have a more uniform shape and size, which Novavax believes will add to the consistency and safety of its vaccines.

"Our VLP technology overcomes a major limitation of the current influenza virus vaccine technology that depends on strain selection and optimization every year.  It enables faster production of vaccine for the target influenza strain than the existing, egg-based process which resulted in significant delays in the manufacture of vaccines during the 2009 H1N1 pandemic emergency," said Dr. Gale Smith, Vice President of Vaccine Development at Novavax and one of the senior inventors of the VLP technology.

"This patent strengthens our competitive position around our core technology that allows us to produce recombinant influenza VLP vaccines.  We are grateful to our scientific team that pioneered this innovative and elegant approach to manufacturing efficient, high-quality, immunogenic influenza vaccines," said Dr. Rahul Singhvi, President and CEO of Novavax.

About Novavax

Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.